Vaginal DNA Assay Shows Promise - Report - MDSpire
Advertisement
Vaginal DNA Assay Shows Promise
A two-marker methylated DNA assay identified endometrial cancer with 96% sensitivity in self-collected vaginal fluid — but prospective validation is needed before it can reduce biopsies in routine care.
A two-marker methylated DNA assay developed by Mayo Clinic shows 96% sensitivity and 82% specificity for detecting endometrial cancer using self-collected vaginal fluid samples. However, these results stem from a case-control study and require further validation in real-world populations before clinical implementation.
Background
Abnormal uterine bleeding affects approximately 1.4 million women annually in the US, with only 5% to 10% of cases linked to endometrial cancer. Current diagnostic methods, such as endometrial biopsy and dilation and curettage, have limitations in sensitivity and patient tolerance. This highlights the need for improved diagnostic tools that can accurately identify endometrial cancer with less procedural burden.
Data Highlights
No numerical data available.
Key Findings
The assay demonstrated 96% sensitivity and 82% specificity in a case-control study.
Self-collected vaginal fluid samples were used for the assay, which is a novel approach.
The study involved 15 institutions and included patients aged 45 and older with abnormal uterine bleeding.
Future validation in a real-world population is necessary to determine negative predictive value.
The assay builds on previous work that identified a 28-marker panel for endometrial cancer detection.
Clinical Implications
The development of this assay may provide a less invasive and more patient-friendly option for detecting endometrial cancer in women with abnormal uterine bleeding. However, clinicians should await further validation studies before considering its use in routine practice.
Conclusion
While the two-marker methylated DNA assay shows promising results, further research is essential to establish its efficacy in broader clinical settings.
Online interest in leucovorin, folate products, and acetaminophen-related autism concerns increased markedly in the 2 weeks following the White House announcement.
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from May 16 - 31.
